摘要
Kaposi’s sarcoma-associated herpesvirus (KSHV) was first identified as the etiologic agent of Kaposi’s sarcoma (KS) in 1994. KSHV infection is necessary,but not sufficient for the development of Kaposi sarcoma (KS),primary effusion lymphoma (PEL),and multicentric Castleman disease (MCD). Advances in the prevention and treatment of KSHV-associated Diseases have been achieved,even though current treatment options are ineffective,or toxic to many affected persons. The identification of new targets for potential future therapies and the randomized trial to evaluate the efficacy of new antivirals are required.
Kaposi＇s sarcoma-associated herpesvirus （KSHV） was first identified as the etiologic agent of Kaposi＇s sarcoma （KS） in 1994. KSHV infection is necessary, but not sufficient for the development of Kaposi sarcoma （KS）, primary effusion lymphoma （PEL）, and multicentric Castleman disease （MCD）. Advances in the prevention and treatment of KSHV-associated Diseases have been achieved, even though current treatment options are ineffective, or toxic to many affected persons. The identification of new targets for potential future therapies and the randomized trial to evaluate the efficacy of new antivirals are required.
基金
National Natural Science Foundation of China (30670093)
关键词
KSHV
疾病
抗病毒药物
治疗方法
临床分析
Antiviral drugs
Kaposi＇s sarcoma-associated herpesvirus （KS HV）
Kaposi＇s sarcoma （KS）
Primaryeffusion lymphoma
Multicentric castleman disease
